76 related articles for article (PubMed ID: 21953447)
1. Hemorphin as a prognostic biomarker and potential drug for breast cancer?
Song CZ; Wang QW; Song CC
Int J Cancer; 2012 Aug; 131(4):1011-2. PubMed ID: 21953447
[No Abstract] [Full Text] [Related]
2. Serum levels of Hemorphin-7 peptides in patients with breast cancer.
Cohen M; Fruitier-Arnaudin I; Sauvan R; Birnbaum D; Piot JM
Clin Chim Acta; 2003 Nov; 337(1-2):59-67. PubMed ID: 14568181
[TBL] [Abstract][Full Text] [Related]
3. Tenascin-W, a new marker of cancer stroma, is elevated in sera of colon and breast cancer patients.
Degen M; Brellier F; Schenk S; Driscoll R; Zaman K; Stupp R; Tornillo L; Terracciano L; Chiquet-Ehrismann R; Rüegg C; Seelentag W
Int J Cancer; 2008 Jun; 122(11):2454-61. PubMed ID: 18306355
[TBL] [Abstract][Full Text] [Related]
4. Serum hemorphin-7 levels are decreased in obesity.
Maraninchi M; Feron D; Fruitier-Arnaudin I; Bégu-Le Corroller A; Nogueira JP; Mancini J; Valéro R; Piot JM; Vialettes B
Obesity (Silver Spring); 2013 Feb; 21(2):378-81. PubMed ID: 23532992
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of serum epidermal growth factor receptor (EGFR) levels in patients with breast cancer.
Tas F; Bilgin E; Karabulut S; Duranyildiz D
Cytokine; 2015 Jan; 71(1):66-70. PubMed ID: 25259789
[TBL] [Abstract][Full Text] [Related]
6. Blood sampling as critical preanalytical determinant to use circulating MMP and TIMP as surrogate markers for pathological processes.
Jung K; Meisser A; Bischof P
Int J Cancer; 2005 Oct; 116(6):1000-1; author reply 1002-3. PubMed ID: 15856460
[No Abstract] [Full Text] [Related]
7. Analysis of acute-phase proteins, AHSG, C3, CLI, HP and SAA, reveals distinctive expression patterns associated with breast, colorectal and lung cancer.
Dowling P; Clarke C; Hennessy K; Torralbo-Lopez B; Ballot J; Crown J; Kiernan I; O'Byrne KJ; Kennedy MJ; Lynch V; Clynes M
Int J Cancer; 2012 Aug; 131(4):911-23. PubMed ID: 21953030
[TBL] [Abstract][Full Text] [Related]
8. Tumor markers in an evidence-based medicine.
Børmer OP
Scand J Clin Lab Invest; 2001; 61(6):417-9. PubMed ID: 11681530
[No Abstract] [Full Text] [Related]
9. New findings offer insight into resistance to breast cancer therapy.
Womens Health (Lond); 2010 Jul; 6(4):493. PubMed ID: 20597624
[No Abstract] [Full Text] [Related]
10. Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer.
Wu ZS; Wu Q; Yang JH; Wang HQ; Ding XD; Yang F; Xu XC
Int J Cancer; 2008 May; 122(9):2050-6. PubMed ID: 18172859
[TBL] [Abstract][Full Text] [Related]
11. Fucosyltransferase IV (FUT4) as an effective biomarker for the diagnosis of breast cancer.
Yan X; Lin Y; Liu S; Aziz F; Yan Q
Biomed Pharmacother; 2015 Mar; 70():299-304. PubMed ID: 25776515
[TBL] [Abstract][Full Text] [Related]
12. Circulating interleukin-6 level is a prognostic marker for survival in advanced nonsmall cell lung cancer patients treated with chemotherapy.
Chang CH; Hsiao CF; Yeh YM; Chang GC; Tsai YH; Chen YM; Huang MS; Chen HL; Li YJ; Yang PC; Chen CJ; Hsiung CA; Su WC
Int J Cancer; 2013 May; 132(9):1977-85. PubMed ID: 23034889
[TBL] [Abstract][Full Text] [Related]
13. The course of serum HER-2/neu levels as an independent prognostic factor for survival in metastatic breast cancer.
Schippinger W; Regitnig P; Bauernhofer T; Ploner F; Hofmann G; Krippl P; Wehrschütz M; Lax S; Carney W; Neumann R; Wernecke KD; Samonigg H
Oncol Rep; 2004 Jun; 11(6):1331-6. PubMed ID: 15138574
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients.
Bachelot T; Ray-Coquard I; Menetrier-Caux C; Rastkha M; Duc A; Blay JY
Br J Cancer; 2003 Jun; 88(11):1721-6. PubMed ID: 12771987
[TBL] [Abstract][Full Text] [Related]
15. Expression of mucin 1 possessing a 3'-sulfated core1 in recurrent and metastatic breast cancer.
Ideo H; Hinoda Y; Sakai K; Hoshi I; Yamamoto S; Oka M; Maeda K; Maeda N; Hazama S; Amano J; Yamashita K
Int J Cancer; 2015 Oct; 137(7):1652-60. PubMed ID: 25787775
[TBL] [Abstract][Full Text] [Related]
16. Is the TNM staging system for breast cancer still relevant in the era of biomarkers and emerging personalized medicine for breast cancer - an institution's 10-year experience.
Orucevic A; Chen J; McLoughlin JM; Heidel RE; Panella T; Bell J
Breast J; 2015; 21(2):147-54. PubMed ID: 25600504
[TBL] [Abstract][Full Text] [Related]
17. The role of cardiac biomarkers as predictors of trastuzumab cardiotoxicity in patients with breast cancer.
Ürun Y; Utkan G; Yalcin B; Akbulut H; Onur H; Oztuna DG; Şenler FC; Demirkazık A; İçli F
Exp Oncol; 2015 Mar; 37(1):53-7. PubMed ID: 25804233
[TBL] [Abstract][Full Text] [Related]
18. Soluble c-Met protein as a susceptible biomarker for gastric cancer risk: A nested case-control study within the Korean Multicenter Cancer Cohort.
Yang JJ; Yang JH; Kim J; Ma SH; Cho LY; Ko KP; Shin A; Choi BY; Kim HJ; Han DS; Eun CS; Song KS; Kim YS; Chang SH; Shin HR; Kang D; Yoo KY; Park SK
Int J Cancer; 2013 May; 132(9):2148-56. PubMed ID: 23001699
[TBL] [Abstract][Full Text] [Related]
19. Circulating levels of endostatin in cancer patients.
Kuroi K; Tanaka C; Toi M
Oncol Rep; 2001; 8(2):405-9. PubMed ID: 11182064
[TBL] [Abstract][Full Text] [Related]
20. Preoperative serum tissue polypeptide-specific antigen is a valuable prognostic marker in breast cancer.
Ahn SK; Moon HG; Ko E; Kim HS; Shin HC; Kim J; You JM; Han W; Noh DY
Int J Cancer; 2013 Feb; 132(4):875-81. PubMed ID: 22815188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
